Skip to main content
Download PDF

Exploring the causal relationship between immune cells and idiopathic pulmonary fibrosis: a bi-directional Mendelian randomization study

BMC Pulmonary Medicine volume 24, Article number: 145 (2024) Cite this article

Abstract

Background

The potential pathogenic mechanism of idiopathic pulmonary fibrosis is widely recognized to involve immune dysregulation. However, the current pool of studies has yet to establish a unanimous agreement regarding the correlation between various types of immune cells and IPF.

Methods

By conducting a two-sample Mendelian randomization analysis using publicly available genetic data, the study examined the causal relationship between IPF and 731 immune cells. To ensure the reliability of the results, combined sensitivity analyses and inverse Mendelian analyses were conducted. Moreover, within subgroups, multivariate Mendelian randomization analyses were utilized to investigate the autonomous causal connection between immune cell characteristics and IPF.

Results

After adjusting for false discovery rate, it was discovered that 20 immunophenotypes exhibited a significant association with IPF. After subgrouping for multivariate Mendelian randomization analysis, there were six immunophenotypes that remained significantly associated with IPF. These included CD33 + HLA DR + CD14dim (OR = 0.96, 95% CI 0.93–0.99, P = 0.033), HLA DR + NK (OR = 0.92, 95% CI 0.85–0.98, P = 0.017), CD39 + CD8 + T cell %T cell (OR = 0.93, 95% CI 0.88–0.99, P = 0.024), CD3 on activated & secreting Treg (OR = 0.91, 95% CI 0.84–0.98, P = 0.026), PDL-1 on CD14- CD16 + monocyte (OR = 0.89, 95% CI 0.84–0.95, P = 8 × 10–4), and CD45 on CD33 + HLA DR + CD14- (OR = 1.08, 95% CI 1.01–1.15, P = 0.011).

Conclusion

Our study reveals a noteworthy association between IPF and various immune cells, providing valuable insights for clinical research and aiding the advancement of immunologically-based therapeutic strategies.

Peer Review reports

Introduction

The incidence of idiopathic pulmonary fibrosis (IPF) is increasing annually, and it is classified as a chronic and fatal interstitial lung disease [1]. According to statistics, it constitutes approximately two-thirds of the diagnosed population aged 60 and above, with a higher prevalence in men compared to women. It affects 10–20 individuals per 100,000 in Europe and the United States, and patients with IPF typically live less than three years on average [2, 3]. However, complete treatment of IPF can only be achieved through lung transplantation techniques. Currently, the main clinical applications to slow down the progression of IPF are FDA-approved nidazanib and pirfenidone. The complexity and unknown etiology of IPF are the primary reasons for its challenging nature [4,5,6].

The cause of IPF is still not fully understood, although research has indicated that inflammation and immune dysregulation play a role. However, the specific immune-related mechanisms are not well understood and are a subject of controversy [7]. In terms of pathophysiology, immune dysregulation acts as a driving force, and dysregulated wound healing resulting from an immune-inflammatory response is one of the factors contributing to IPF. Furthermore, the presence of elevated pro-fibrotic cytokines (i.e. interleukin-8 (IL-8) and TNF-α) and immune abnormalities in the lungs of patients with IPF support the inflammatory hypothesis [8, 9]. However, attempts to treat IPF by modulating inflammation in clinical trials have unfortunately had negative effects [10,11,12]. There is growing evidence suggesting that IPF is closely linked to both the innate and adaptive immune systems [13]. Immune cells, including monocytes, T cells, macrophages, and natural killer (NK) cells, are primarily responsible for causing IPF [14]. Cytokines such as IL-6 and IL-23 induce various type 17 immune cells (such as regulatory T cells (Tregs), CD8 + T cells, and NKT cells) to produce IL-17A, which in turn induces TGF-β and leads to pulmonary fibrosis [15]. Targeted therapy for type 17 immunity is considered a new treatment strategy. Therefore, it is expected that more targets that inhibit the development of IPF in an immunological sense will be discovered.

Mendelian randomization (MR), a crucial epidemiological approach, relies on the independent distribution laws of Mendel. It utilizes SNPs (single nucleotide polymorphisms) to mimic and determine if risk factors impact health outcomes, effectively removing biases from confounding factors and reverse causation. The progress made in genome-wide association studies (GWAS) and MR has facilitated the easier assessment of causal connections between diseases and immune traits [16]. Numerous studies have provided evidence supporting the notion that IPF is linked to immune cells [14, 15]. Hence, we employed extensive two-sample MR analyses to examine the causal relationship between IPF and 731 immune traits. The validity of the findings was reinforced through sensitivity analyses, reverse MR, and multivariate mendelian randomization (MVMR) analyses. The objective of our research is to uncover the potential impact of immune cell characteristics in IPF and potentially identify novel approaches for disease prediction and treatment. Figure 1 depicts the entire research process.

Fig. 1
figure 1

Overall workflow of our research. The Global Biobank Meta-analysis Initiative (GBMI) refers to Genome-wide Association Studies (GWAS). Created with BioRender.com

Full size image

Materials and methods

Study design

Analyzing GWAS data, we investigated the reciprocal causal relationships between IPF risk and immune cells (731 samples from seven immune panels). For causal inference to be effective, risk factors and reliable instrumental variables (IVs) must be captured. It is imperative to satisfy three fundamental assumptions: (1) the existence of a direct association between genetic variation and exposure; (2) the absence of correlation between genetic variation and potential confounding factors that lie between exposure and outcome; and (3) the non-influence of genetic variation on the outcome through alternative pathways apart from the exposure. The institutional review boards have approved all studies included in the data.

Data sources

Summary statistics for immune traits obtained from genome-wide association studies (GWAS) can be accessed through the GWAS Catalog, specifically the catalog entries GCST0001391 to GCST0002121 [16]. The study examined a total of 118 absolute cell (AC) quantities, 389 median fluorescence intensities (MFI) representing surface antigen levels, 192 relative cell quantities (RC), and 32 structural features (MP) using flow cytometry. To analyze the GWAS data, we investigated the reciprocal causal relationships between a specific set of immune cells (across seven immune panels, totaling 731 samples) and the risk of developing diseases. In a population from Sardinia consisting of 3,757 individuals, we evaluated a total of 731 immunotypes. We genotyped the samples using four Illumina arrays (ExomeChip, Cardio-MetaboChip, ImmunoChip, and OmniExpress) and then imputed the genotypes across the entire genome using a reference panel comprised of 3,514 Sardinian sequences. After accounting for covariates such as age, gender, and age squared, we tested the associations using the Sardinian sequence-based reference panel to impute approximately 22 million SNPs genotyped with high-density arrays [17]. As for IPF, the data consisted of 6,257 cases and 947,616 controls, which were obtained from the most recent meta-analysis of GWAS summary statistics conducted by the Global Biobank Meta-analysis Initiative (GBMI) [18].

Selection of instrumental variables

In accordance with recent research, the significance level of IVs for each immune trait was set to 1 × 10–5 [16, 19]. To remove these SNPs (with a linkage disequilibrium [LD] r2 threshold < 0.001 within a distance of 10,000 kb) [20], the PLINK software (version v1.90) employed the clumping procedure, with LD r2 calculated using the 1000 Genomes Projects as a reference panel. In order to assess the strength of the extracted IVs, we computed the R2 and F-value for each IV to prevent any potential instrumental bias caused by weak instruments. We eliminated IVs from our analysis that had low F statistics (F < 10). Additionally, to avoid reverse causality and detect whether the correlation between SNPs and outcome was greater than exposure, we conducted the Steiger Test for further screening. For further reverse MR validation, for IPF, we modified the significance level to 5 × 10 −8 and identified ten IVs.

Mendelian randomization

The study utilized various methods, such as inverse variance weighted (IVW), MR-Egger, weighted median, weighted mode, maximum likelihood (ML) and Simple mode, to investigate if there existed a causal link between 731 immunophenotypes and IPF. To obtain an overall estimate of the impact of immunotypes on IPF, the IVW technique employed a meta-analysis approach in conjunction with Wald estimates for each SNP. In the absence of horizontal pleiotropy, the IVW findings would remain unbiased [21]. The MR-Egger method relies on the assumption of instrument strength that is not influenced by direct effects (InSIDE). This assumption allows for the assessment of pleiotropy by considering the intercept term. When the intercept term is zero, it suggests the absence of horizontal pleiotropy, and the outcome of the MR-Egger regression aligns with IVW [22]. The weighted median provides a precise estimation by assuming that a minimum of 50% of the IVs are valid [23]. The ML approach is comparable to IVW, under the assumption that there is no heterogeneity or horizontal pleiotropy. Assuming the hypotheses are met, the outcomes will be impartial, and the standard deviations will be less than IVW [24]. When the InSIDE hypothesis is not upheld, the weighted model estimate has demonstrated enhanced ability in identifying a causal effect, reduced bias, and decreased occurrence of type I errors compared to MR-Egger regression [23]. Despite not being as powerful as IVW, simple mode offers robustness for pleiotropy [25]. In order to evaluate the causal relationship between immunophenotypes and IPF, we conducted reverse MR analysis on the immunophenotypes that were determined to have a causal association with IPF in the forward MR analysis. The techniques and configurations utilized were in line with those of forward MR.

Sensitivity analysis

The Cochran’s IVW Q statistics were used to assess the diversity of IVs. In case there was diversity in the estimated impact, we substituted the standard fixed-effects IVW with the random-effects IVW technique [26]. To detect the existence of horizontal pleiotropy, the MR-Egger method was employed with caution. If the MR-Egger intercept was found to be statistically significant, it indicated that the association findings might be affected by horizontal pleiotropic effects of other characteristics [27]. To exclude possible horizontal pleiotropy, the global test MR-PRESSO (MR pleiotropy residual sum and outlier) was also performed to determine if there were any outliers [28]. Additionally, as part of "leave-one-out" analysis, each instrumental SNP was omitted in turn in an effort to identify potentially heterogeneous SNPs. The scatter diagrams indicated that the outcomes were not influenced by anomalies, while the Leave-one-out plots exhibited the resilience of the association.

Multivariable MR

In order to evaluate the independent causal impact of immune cell traits on IPF, we performed the MVMR analysis [29] by categorizing them into various subgroups according to traits type. This expands upon univariate MR by enabling the simultaneous identification of causal effects from multiple risk factors. MVMR considers the interrelation between different immune phenotypes within subgroups [30]. The SNPs utilized for conducting MVMR were combinations of IVs for each exposure. We restricted the analysis to SNPs that were clumped on r2 < 0.001 within 10000 kb.

Statistical analysis

The presentation of odds ratios (OR) and 95% confidence intervals (95% CI) in the statistical results indicates significance when P < 0.05. In order to interpret causality more rigorously, the significance threshold was adjusted according to the false discovery rate (FDR) method. The analyses were conducted using the R 3.5.3 software, which can be found at https://www.Rproject.org. The packages “fdrtool”, “TwoSampleMR” [31] and “MendelianRandomization” in R were utilized for MR analyses and clumping. Finally, MR-PRESSO was performed by the MR-PRESSO package.

Results

Causal effect between immunophenotypes and IPF risk

A total of 14,997 SNPs were utilized to analyze 731 immunophenotypes, following the selection criteria for IVs. Supplementary Table 1 displays information regarding the chosen IVs. A two-sample MR analysis was conducted to examine the causal effects of IPF on immunophenotypes, with the IVW method employed as the primary approach. After applying FDR adjustment (PFDR < 0.05), a total of 20 immunophenotypes were identified to have significant associations with IPF (Supplementary Table 2). A total of nine were observed in the TBNK panel, while three were observed in the Treg panel. Additionally, two were observed in each of the myeloid cell, monocyte, and B-cell panels. Furthermore, one was observed in both the myeloid cell and monocyte panels, and one was observed in the T-cell panel at the maturation stage.

Among the 20 immunophenotypes, those positively associated with IPF risk are CD4/CD8br (OR = 1.12, 95% CI 1.03 ~ 1.22, P = 0.009, PFDR = 0.029), CD8dim %T cell (OR = 1.12, 95% CI 1.03 ~ 1.22, P = 0.010, PFDR = 0.033), CD8dim NKT %T cell (OR = 1.11, 95% CI 1.05 ~ 1.18, P = 9.92 × 10–4, PFDR = 0.003), CD8dim NKT %lymphocyte (OR = 1.08, 95% CI 1.02 ~ 1.14, P = 0.005, PFDR = 0.015), DN (CD4-CD8-) NKT %T cell (OR = 1.08, 95% CI 1.02 ~ 1.14, P = 0.007, PFDR = 0.022), CD45 on CD33br HLA DR + CD14- (OR = 1.07, 95% CI 1.01 ~ 1.12, P = 0.018, PFDR = 0.038), CD45 on Mo MDSC (OR = 1.07, 95% CI 1.02 ~ 1.13, P = 0.008, PFDR = 0.026) and CD14 + CD16- monocyte %monocyte (OR = 1.05, 95% CI 1.01 ~ 1.09, P = 0.011, PFDR = 0.037). Of these 20 immunophenotypes, the ones that are negatively correlated with IPF risk are TCRgd %T cell (OR = 0.93, 95% CI 0.88 ~ 0.98, P = 0.007, PFDR = 0.034), TCRgd %lymphocyte (OR = 0.96, 95% CI 0.96 ~ 1.00, P = 0.041, PFDR = 0.049), HLA DR + NK (OR = 0.91, 95% CI 0.85 ~ 0.97, P = 0.002, PFDR = 0.008), SSC-A on lymphocyte (OR = 0.90, 95% CI 0.83 ~ 0.98, P = 0.013, PFDR = 0.040), SSC-A on lymphocyte (OR = 0.96, 95% CI 0.93 ~ 0.99, P = 0.007, PFDR = 0.025), CD14 + CD16 + monocyte %monocyte (OR = 0.94, 95% CI 0.88 ~ 0.99, P = 0.023, PFDR = 0.042), PDL-1 on CD14- CD16 + monocyte (OR = 0.92, 95% CI 0.86 ~ 0.97, P = 0.002, PFDR = 0.011), CD39 + CD8br %T cell (OR = 0.93, 95% CI 0.87 ~ 0.99, P = 0.018, PFDR = 0.044), CD3 on activated & secreting Treg (OR = 0.94, 95% CI 0.89 ~ 0.98, P = 0.008, PFDR = 0.029), CD3 on CD28- CD8br (OR = 0.91, 95% CI 0.85 ~ 0.98, P = 0.015, PFDR = 0.046), CD19 on IgD + CD38- naive (OR = 0.95, 95% CI 0.91 ~ 1.00, P = 0.037, PFDR = 0.045) and CD45RA on naive CD8br (OR = 0.91, 95% CI 0.86 ~ 0.97, P = 0.005, PFDR = 0.022). The results of MR-Egger, weighted median, ML, weighted mode, and simple mode all align with the IVW results. The forest plot of all significant associations is shown as Fig. 2. Furthermore, the presence of horizontal pleiotropy was excluded by both the MR-Egger intercept and the MR-PRESSO global test, as shown in Supplementary Tables 3 and 4. According to the sensitivity analysis, the observed causal associations were robust. The stability of the results was also demonstrated by scatter plots and leave-one-out plots (Figs. 3 and 4). Finally, to evaluate reverse causal effects, we utilized IPF as the exposure, 20 immunophenotypes as the outcome, and 10 SNPs associated with IPF extracted from a previous GWAS as the IVs. Notably, no reverse causality was observed (PFDR > 0.05) (Supplementary Table 5).

Fig. 2
figure 2

Various techniques were employed in the forest plots to demonstrate the causal connections between immune cell characteristics and IPF.SNP refers to single nucleotide polymorphism, OR stands for odds ratio, and CI represents confidence interval

Full size image
Fig. 3
figure 3

Graphs illustrating the correlation between IPF risk and 20 immune cells. The scatter plot includes an x-axis to illustrate the magnitude of the exposure SNP effect, while a y-axis is utilized to represent the outcome SNP effect

Full size image
Fig. 4
figure 4

A leave-one-out analysis of 20 immune cells and IPF

Full size image

Multivariable MR analysis

Multivariate MR analysis performed in subgroups based on four types (AC, RC, MP, MFI) of immune traits. The MP type was excluded from the further analysis due to only one immune phenotype. After adjusting for other immune cell characteristics within subgroups, there was a significant causal association between IPF and 6 immune cell traits (Fig. 5): CD33 + HLA DR + CD14dim (OR = 0.96, 95% CI 0.93 ~ 0.99, P = 0.033), HLA DR + NK (OR = 0.92, 95% CI 0.85 ~ 0.98, P = 0.017), CD39 + CD8 + T cell %T cell (OR = 0.93, 95% CI 0.88 ~ 0.99, P = 0.024), CD3 on activated & secreting Treg (OR = 0.91, 95% CI 0.84 ~ 0.98, P = 0.026), PDL-1 on CD14- CD16 + monocyte (OR = 0.89, 95% CI 0.84 ~ 0.95, P = 8 × 10–4), CD45 on CD33 + HLA DR + CD14- (OR = 1.08, 95% CI 1.01 ~ 1.15, P = 0.011). In addition, 13 other immune cell phenotypes (i.e., CD14 + CD16 + monocyte %monocyte, CD14 + CD16- monocyte %monocyte, CD4/CD8br, CD8dim %T cell, TCRgd %T cell, TCRgd %lymphocyte, CD8dim NKT %T cell, CD8dim NKT %lymphocyte, DN (CD4-CD8-) NKT %T cell, CD19 on IgD + CD38- naive, CD45 on Mo MDSC, CD3 on CD28- CD8br, CD45RA on naive CD8br) lost statistical significance after adjustment.

Fig. 5
figure 5

A forest diagram illustrating the association between twenty different immune cells and the risk of developing IPF using multivariable MR analysis.OR, odds ratio; CI, confdence interval

Full size image

Discussion

A thorough examination of extensive genetic data was undertaken to explore the genetic association between IPF and 731 immune cell traits. The outcomes of this study provide compelling evidence suggesting the involvement of immune cells in influencing the susceptibility to IPF. The study utilized a two-sample MR method to validate that 20 immune traits were significantly linked to the risk of IPF (PFDR < 0.05). The development of IPF may potentially be linked to various immune cells.

Recently, the results of the CAMPUCITY and INSPIRE trials found a strong association between monocytes and the risk of disease progression and death in IPF, and proposed monocyte counts as a biomarker for predicting prognosis in IPF [32]. The results of our study revealed a negative association between the expression of PDL-1 on CD14- CD16 + monocytes and the susceptibility to IPF. In the innate immune system, monocytes and macrophages serve as immune sentinels, primarily characterized by the presence of CD14 and CD16, which are essential for cellular participation in fibrosis. Phenotypic markers can be utilized to classify monocyte subsets into intermediate (CD16 + CD14 +), classic (CD16-CD14 +) and non-classical (CD16 + CD14 −) categories [33]. Many researches have revealed that CD14 + CD16- classical monocytes can mature into macrophages in the early stages of fibrosis and are closely associated with the development of IPF [33,34,35]. Interestingly, in our study, IPF declined with increasing CD14 + CD16 + monocyte %monocyte ratio, whereas past studies have indicated that intermediate monocytes are associated with a worse prognosis in IPF patients [36]. Furthermore, it has been reported that the combination of pirfenidone and a PDL-1 inhibitor improves the efficacy of treatment in lung cancer patients with IPF [37]. Blocking the PD-1 pathway also reduces pro-fibrotic factors such as IL-17 and TGF-β production [38]. Thus, these findings provide new insights for us to continue exploring the role of monocytes in IPF and new therapeutic targets.

It has also been found that HLA DR + NK AC is strongly linked to decreased susceptibility to IPF. In various fibrotic model systems, NK cells primarily demonstrate anti-fibrotic properties [39]. In addition, patients with pulmonary infection with mycobacterium tuberculosis have a higher probability of developing IPF, and the number of NK cells in lymphocytes isolated from bronchoalveolar lavage fluid is lower in IPF patients [40]. Currently, pre-activated HLA-DR NK cells in vitro have been considered as a target subpopulation for anti-tuberculosis therapies due to the important role they can play in different stages of mycobacterium tuberculosis infection [41, 42]. Additionally, this phenomenon offers a significant opportunity for impeding the progression of IPF. Moreover, HLA-DR NK cells possess the capacity to selectively bind particular antigens, subsequently presenting them to CD4 and CD8 T cells, thereby inducing their activation and subsequent proliferation [43]. Our study found a negative correlation between the risk of IPF and the percentage of CD39 + CD8 + T cells. The involvement of T cells in IPF remains a subject of debate, with animal models of pulmonary fibrosis showing that T cells can have either harmful or beneficial effects depending on their characteristics. The use of targeted T cells has become less popular due to the ineffectiveness of anti-inflammatory therapies in IPF patients.

Our findings also indicate that an increase in the ratio of CD3 on activated & secreting Tregs could reduce the occurrence of IPF, which is consistent with the previous discovery that Tregs are protective in IPF through reducing fibroblast accumulation and inhibiting inflammatory responses [44, 45]. Recent data suggest that Tregs might play diverse roles in the early and late stages of fibrosis. In addition, cells like CD8dim NKT %T cell and CD8dim NKT %lymphocyte can increase the risk of IPF. CD8dim NKT belongs to the classical NKT cells with dual immunoregulatory roles and is able to secrete pro-fibrotic factors such as IFN-γ and IL-17A [46]. IL-17A, in particular, can trigger epithelial-mesenchymal transition (EMT) in alveolar epithelial cells through TGF-β. This process is believed to contribute to lung fibrosis. By blocking IL-17A through TGF-β1-dependent and non-dependent mechanisms, it is possible to suppress lung inflammation and fibrosis [47, 48]. Current research on the role of immune cells in IPF remains limited. In addition to the immune cells mentioned above, there are also some cells such as TCRgd% T cells that have been shown in previous experimental reports to produce IFN-γ, thereby inhibiting the progression of IPF. However, there are numerous immune phenotypes that have not yet been thoroughly investigated by researchers in our study and the underlying mechanisms remain largely unknown. In addition, studies of various immunophenotypes are commonly used by investigators to predict and determine prognosis. For example, T-cell related proteins and genes, LCK and CD28, have been used as prognostic biomarkers for IPF [49]. In terms of clinical treatments, the recently proposed mesenchymal stem cell(MSC) therapy is continuously supported by many preclinical evidences. The mouse model of this therapy showed a significant reduction in inflammatory cells and even an increase in regulatory T cells with anti-inflammatory effects, making this a promising therapeutic strategy [50]. With the exception of pirfenidone and nintedanib, most of the drugs are still in clinical trials. In the latest study [51], TH5487 targeted inhibition of OGG1, inflammatory macrophages and neutrophils were found to be significantly reduced and ameliorated lung injury, so this may lead to a new way of thinking about designing the appropriate drug to treat IPF.

The current study is grounded on a two-sample MR analysis, utilizing published findings from a substantial GWAS cohort comprising approximately 150,000 individuals, thereby ensuring its statistical robustness. The study's findings were derived from genetic IVs, and causal inferences were drawn using various MR analysis techniques. Furthermore, our results exhibit robustness, as they remain unaffected by horizontal pleiotropy and other confounding factors.

The limitations of this study must, however, be acknowledged. Firstly, despite implementing the FDR multiple correction, the liberal threshold for SNP selection owing to the constrained sample size may lead to a certain extent of spurious positive findings. Subsequently, despite conducting multiple sensitivity analyses, a comprehensive evaluation of horizontal pleiotropy could not be achieved. Thirdly, our analyses were conducted using aggregated-level datasets, with individual-level data being unavailable. Consequently, the present study was unable to perform additional stratification of the traits of interest based on group characteristics such as gender, age, etc. Last, since this research relies on a European database, the outcomes cannot be extrapolated to other ethnicities, thereby restricting the generalizability of our findings.

Conclusion

To summarize, our results indicate that 20 immune cells may play a causal role in IPF based on a thorough bidirectional MR analysis. In our study, we have successfully mitigated the effect of inevitable confounding variables, reverse causality, and additional factors that might influence our findings. Consequently, it offers a promising avenue for researchers to investigate the fundamental biological mechanisms of IPF, gain novel insights into the immunology of IPF pathogenesis, and acquire valuable indications for early intervention and treatment.

Availability of data and materials

The datasets presented in this study can be found in online repositories. Data URLs: GWAS summary statistics for 731 immune traits could be download form GWAS Catalog (Study accession: GCST90001001—GCST90002000, https://www.ebi.ac.uk/gwas/home); IPF could be available form http://results.globalbiobankmeta.org/pheno/IPF. All codes used in the research are available from the corresponding authors.

Abbreviations

AC:

Absolute cell

CI:

Confidence interval

EMT:

Epithelial-mesenchymal transition

FDR:

False discovery rate

GWAS:

Genome-wide association study

GBMI:

Global Biobank Meta-analysis Initiative

HLA:

Human leukocyte antigen

IPF:

Idiopathic pulmonary fibrosis

IL:

Interleukin

IVs:

Instrumental variables

IVW:

Inverse variance weighting

LD:

Linkage disequilibrium

MR:

Mendelian Randomization

MFI:

Median fluorescence intensities

MP:

Morphological parameters

ML:

Maximum likelihood

MR-PRESSO:

MR pleiotropy residual sum and outlier

MVMR:

Multivariate mendelian randomization

NK:

Natural killer

OR:

Odds ratio

RC:

Relative cell

SNPs:

Single nucleotide polymorphisms

Tregs:

Regulatory T cells

References

  1. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806.

    Article  PubMed  Google Scholar 

  2. Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J. 2016;48(1):179–86.

    Article  PubMed  Google Scholar 

  3. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355–61.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

    Article  PubMed  PubMed Central  Google Scholar 

  5. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    Article  PubMed  Google Scholar 

  6. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–9.

    Article  PubMed  Google Scholar 

  7. Fernandez IE, Greiffo FR, Frankenberger M, Bandres J, Heinzelmann K, Neurohr C, Hatz R, Hartl D, Behr J, Eickelberg O. Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis. Eur Respir J. 2016;48(4):1171–83.

    Article  CAS  PubMed  Google Scholar 

  8. Parra ER, Kairalla RA, de RibeiroCarvalho CR, Eher E, Capelozzi VL. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration. 2007;74(2):159–69.

    Article  CAS  PubMed  Google Scholar 

  9. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2163–9.

    Article  CAS  PubMed  Google Scholar 

  10. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.

    Article  CAS  PubMed  Google Scholar 

  11. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (London, England). 2009;374(9685):222–8.

    Article  CAS  PubMed  Google Scholar 

  12. Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017;5(1):22–32.

    Article  CAS  PubMed  Google Scholar 

  13. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021;131(2):e143226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91.

    Article  CAS  PubMed  Google Scholar 

  16. Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, Sole G, Lai S, Dei M, Mulas A, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52(10):1036–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sidore C, Busonero F, Maschio A, Porcu E, Naitza S, Zoledziewska M, Mulas A, Pistis G, Steri M, Danjou F, et al. Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. Nat Genet. 2015;47(11):1272–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Partanen JJ, Häppölä P, Zhou W, Lehisto AA, Ainola M, Sutinen E, Allen RJ, Stockwell AD, Leavy OC, Oldham JM, et al. Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. Cell genomics. 2022;2(10):100181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yu XH, Yang YQ, Cao RR, Bo L, Lei SF. The causal role of gut microbiota in development of osteoarthritis. Osteoarthritis Cartilage. 2021;29(12):1741–50.

    Article  PubMed  Google Scholar 

  20. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.

    Article  ADS  PubMed  Google Scholar 

  21. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880–906.

    Article  MathSciNet  PubMed  Google Scholar 

  22. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177–84.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12):1767–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333–55.

    Article  MathSciNet  PubMed  Google Scholar 

  27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–89.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251–60.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48(3):713–27.

    Article  PubMed  Google Scholar 

  31. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Atwood M, Kirchgaessler KU, Maher TM. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(1):74–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol. 2013;4:23.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.

    Article  CAS  PubMed  Google Scholar 

  35. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392–404.

    Article  CAS  PubMed  Google Scholar 

  36. Moore BB, Fry C, Zhou Y, Murray S, Han MK, Martinez FJ, Flaherty KR. Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. Front Med. 2014;1(56):56.

    PubMed  PubMed Central  Google Scholar 

  37. Qin W, Zou J, Huang Y, Liu C, Kang Y, Han H, Tang Y, Li L, Liu B, Zhao W, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology. 2020;9(1):1824631.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med. 2018;10(460):eaar8356.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R. The immunology of fibrosis: innate and adaptive responses. Trends Immunol. 2010;31(3):110–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Gruber R, Pforte A, Beer B, Riethmüller G. Determination of gamma/delta and other T-lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung. APMIS. 1996;104(3):199–205.

    Article  CAS  PubMed  Google Scholar 

  41. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology. 2009;128(2):151–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kust SA, Streltsova MA, Panteleev AV, Karpina NL, Lyadova IV, Sapozhnikov AM, Kovalenko EI. HLA-DR-Positive NK Cells Expand in Response to Mycobacterium Tuberculosis Antigens and Mediate Mycobacteria-Induced T Cell Activation. Front Immunol. 2021;12:662128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Erokhina SA, Streltsova MA, Kanevskiy LM, Grechikhina MV, Sapozhnikov AM, Kovalenko EI. HLA-DR-expressing NK cells: Effective killers suspected for antigen presentation. J Leukoc Biol. 2021;109(2):327–37.

    Article  CAS  PubMed  Google Scholar 

  44. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, Sotiriou I, Aidinis V, Margaritis D, Tsatalas C, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(12):1121–30.

    Article  CAS  PubMed  Google Scholar 

  45. Fu XY, Zhang DW, Li YD, Zhao PW, Tang YQ, Niu JZ, Li Y. Curcumin treatment suppresses CCR7 expression and the differentiation and migration of human circulating fibrocytes. Cell Physiol Biochem. 2015;35(2):489–98.

    Article  CAS  PubMed  Google Scholar 

  46. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, di Padova F, Fick L, Charron S, Lagente V, Eberl G, et al. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One. 2011;6(8):e23185.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  47. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol (Baltimore, Md : 1950). 2011;187(6):3003–14.

    Article  CAS  Google Scholar 

  48. Wang T, Liu Y, Zou JF, Cheng ZS. Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-β1 mediated Smad2/3 and ERK1/2 activation. PLoS One. 2017;12(9):e0183972.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Deng L, Huang T, Zhang L. T cells in idiopathic pulmonary fibrosis: crucial but controversial. Cell Death Discov. 2023;9(1):62.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Buschur KL, Riley C, Saferali A, Castaldi P, Zhang G, Aguet F, Ardlie KG, Durda P, Craig Johnson W, Kasela S, et al. Distinct COPD subtypes in former smokers revealed by gene network perturbation analysis. Respir Res. 2023;24(1):30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Tanner L, Single AB, Bhongir RKV, Heusel M, Mohanty T, Karlsson CAQ, Pan L, Clausson CM, Bergwik J, Wang K, et al. Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model. Nat Commun. 2023;14(1):643.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to Biorender for its assistance in figure design. In addition, We thank all the consortiums for making the summary association statistics data publicly available, and we are grateful to the participants and many researchers involved in proteome GWAS studies. Finally, We also appreciate all peer reviewers for their comments and suggestions.

Funding

This work was partially supported by the Natural Science Foundation of Jiangsu Province (BK20210068), the Top Talent Support Program for Young and Middle-aged People of Wuxi Municipal Health Commission (HB2020003), the Mega-project of Wuxi Commission of Health (Z202216), the General Program of Wuxi Medical Center of Nanjing Medical University (WMCG202305) and the High-end Medical Expert Team of the 2019 Taihu Talent Plan (2019-THRCTD-1).

Author information

Author notes

  1. Zhao He, Ruixin Wang and Chenghu Song contributed equally to this work.

Authors and Affiliations

  1. Department of Thoracic Surgery, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, No. 299 Qingyang Rd, Wuxi, 214023, China

    Zhao He, Ruixin Wang, Chenghu Song, Jiwei Liu, Ruo Chen, Mingfeng Zheng, Weici Liu, Guanyu Jiang & Wenjun Mao

Authors
  1. Zhao He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruixin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chenghu Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ruo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mingfeng Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weici Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Guanyu Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenjun Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Wenjun Mao, Guanyu Jiang designed the study and participated in coordination and project control. Jiwei Liu, Ruo Chen and Mingfeng Zheng collected the public data and conducted the analysis. Zhao He, Ruixin Wang and Chenghu Song wrote the draft. Wenjun Mao and Weici Liu revised the manuscript. Wenjun Mao got financial support. All authors reviewed and approved the final edition.

Corresponding authors

Correspondence to Weici Liu, Guanyu Jiang or Wenjun Mao.

Ethics declarations

Ethics approval and consent to participate

This study was conducted using published studies and publicly available summary statistics. All original studies were approved by the appropriate ethical review commissions and all participants provided informed consent. Besides, no individual-level data was used in this study, no new ethical commission approval was required.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, Z., Wang, R., Song, C. et al. Exploring the causal relationship between immune cells and idiopathic pulmonary fibrosis: a bi-directional Mendelian randomization study. BMC Pulm Med 24, 145 (2024). https://doi.org/10.1186/s12890-024-02942-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-024-02942-w

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us